Oct 2026· Medicina· Vol 62· 0 citations· 25 references
Medicine
TL;DR
Early dynamic 18F-FDG PET/CT imaging at 0–2 min showed the highest, although modest, diagnostic performance among the evaluated time points for predicting tumor grade and muscle invasion.
Abstract
Background and Objectives: Accurate preoperative staging and grade assessment are crucial for optimal treatment selection in bladder cancer. This prospective study evaluated multi-timepoint Fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) imaging for predicting pathological stage and tumor grade. Materials and Methods: Seventy-two patients with bladder carcinoma underwent 18F-FDG PET/CT including early dynamic (0–2, 2–4, 8–10 min), standard (60 min), and late (~120 min) imaging following a standardized furosemide hydration protocol. Maximum standardized uptake values (SUVmax) were correlated with histopathological findings. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis with Youden index for optimal cut-offs. Results: The cohort comprised 72 patients (84.7% male, mean age 64.8 ± 10.7 years) with pathological stages Ta (36.1%), CIS (15.3%), T1 (31.9%), and T2 (16.7%). High-grade tumors demonstrated significantly higher SUVmax at early dynamic imaging (0–2 min: 1.50 vs. 1.00, p = 0.028) and late imaging (11.40 vs. 9.50, p = 0.045) compared to low-grade tumors. Early dynamic imaging at 0–2 min achieved the highest, although modest, diagnostic performance for high-grade prediction (area under the curve (AUC) = 0.652) and muscle-invasive disease prediction (AUC = 0.669), with optimal cut-offs of SUVmax = 1.40 and 1.80, respectively. Early dynamic SUVmax correlated significantly with tumor grade (ρ = 0.261, p = 0.027) and tumor size (ρ = 0.424, p < 0.001). The negative predictive value for muscle-invasive disease was 90.4%, but sensitivity was only 58.3%. Conclusions: Early dynamic 18F-FDG PET/CT imaging at 0–2 min showed the highest, although modest, diagnostic performance among the evaluated time points for predicting tumor grade and muscle invasion. The identified SUVmax cut-offs are exploratory and require external validation in larger multicenter studies before clinical use. Trial registration: Not registered.
OBJECTIVES
To evaluate the incremental clinical value of [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) beyond contrast-enhanced computed tomography (CECT) for primary staging of suspected high-risk upper tract urothelial carcinoma (UTUC).
PATIENTS AND METHODS
We conducted...
R. A. G. Lijnen, J. Ringia, K. Hendricksen et al.· BJU International· 0 citations
Purpose To assess the predictive value of preoperative 2-deoxy-2-[¹8F]fluoro-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) imaging parameters in forecasting the recurrence and metastasis following surgery among individuals diagnosed with early-stage breast cancer. Methods A retrospective...
N. Lin, Chao Ren, Zhe Wen· Frontiers in Oncology· 0 citations
This study aimed to evaluate the clinical value of fluorine-18-labeled fluorodeoxyglucose (18F-FDG) PET/computed tomography (CT) in managing primary malignant melanoma of the esophagus (PMME). Seventy patients with pathologically confirmed PMME between September 2011 and June 2025 were retrospectively analyzed. The dia...
Fei Wang, Xiang-Xi Meng, R. Guo et al.· Melanoma research· 0 citations
Post-treatment FDG-PET/CT is a valuable prognostic tool in HNSCC follow-up, especially when evaluated after three months, is predictive of disease progression, and integrating PET/CT into routine surveillance may improve risk stratification and inform tailored follow-up intensity.
Thomas Hebisch, Kerem Tuna Tas, Philipp Lishewski et al.· Frontiers in Oncology· 0 citations
Combining CT radiomics and SUVmax with clinicopathological biomarkers yielded the highest numerical discrimination for pCR, but improvement over the Clinical model was modest.
Filiz Hatipoğlu, Ozcan Senmevsim, E. Kahraman et al.· Nuclear medicine communicati...· 0 citations